Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) was upgraded by Vetr from a “buy” rating to a “strong-buy” rating in a note issued to investors on Thursday. The brokerage presently has a $14.00 price objective on the biopharmaceutical company’s stock. Vetr‘s price target indicates a potential upside of 13.73% from the stock’s current price.
SCMP has been the subject of a number of other reports. Mizuho reissued a “buy” rating on shares of Sucampo Pharmaceuticals in a research note on Monday, July 11th. Maxim Group dropped their target price on shares of Sucampo Pharmaceuticals from $26.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, August 1st. Zacks Investment Research upgraded shares of Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, August 8th. Jefferies Group dropped their target price on shares of Sucampo Pharmaceuticals from $16.00 to $14.00 and set a “hold” rating for the company in a research report on Thursday, August 4th. Finally, Northland Securities assumed coverage on shares of Sucampo Pharmaceuticals in a research report on Wednesday, September 7th. They set an “outperform” rating and a $15.00 target price for the company. Five analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $18.73.
Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at 12.31 on Thursday. The stock has a market cap of $526.99 million, a PE ratio of 43.19 and a beta of 1.28. The firm has a 50 day moving average of $11.96 and a 200-day moving average of $11.39. Sucampo Pharmaceuticals has a 52-week low of $9.59 and a 52-week high of $22.11.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.01. The firm earned $52 million during the quarter, compared to analysts’ expectations of $48.33 million. Sucampo Pharmaceuticals had a net margin of 6.65% and a return on equity of 42.18%. The company’s revenue for the quarter was up 49.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.21 earnings per share. Equities analysts anticipate that Sucampo Pharmaceuticals will post $1.03 earnings per share for the current fiscal year.
Large investors have recently made changes to their positions in the stock. Zacks Investment Management purchased a new stake in shares of Sucampo Pharmaceuticals during the second quarter valued at $110,000. Boothbay Fund Management LLC purchased a new stake in shares of Sucampo Pharmaceuticals during the first quarter valued at $114,000. Smith Asset Management Group LP increased its stake in shares of Sucampo Pharmaceuticals by 69.5% in the second quarter. Smith Asset Management Group LP now owns 10,730 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 4,400 shares in the last quarter. Princeton Alpha Management LP purchased a new stake in shares of Sucampo Pharmaceuticals during the second quarter valued at $138,000. Finally, UBS Asset Management Americas Inc. purchased a new stake in shares of Sucampo Pharmaceuticals during the second quarter valued at $144,000. 40.64% of the stock is currently owned by institutional investors and hedge funds.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.